Company news

CareDx, Inc. news in 2025

CareDx, Inc.'s news releases, calls and decks from 2025, newest first.

View company

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 25, 2025

CareDx Provides Notice of Proposed Derivative Settlement

December 18, 2025

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

November 23, 2025

CareDx to Participate in Upcoming Investor Conferences

November 9, 2025

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

November 5, 2025

CareDx Announces Third Quarter 2025 Financial Results

November 3, 2025

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

October 26, 2025

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

October 22, 2025

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

October 21, 2025

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

October 20, 2025

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

October 5, 2025

CareDx Issues Comment Letter on Draft LCD Policy

September 1, 2025

CareDx to Participate in Wells Fargo Healthcare Conference

August 20, 2025

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

August 12, 2025

CareDx Announces Second Quarter 2025 Financial Results

August 6, 2025

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

August 5, 2025

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

August 5, 2025

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

July 30, 2025

CareDx to Report Second Quarter 2025 Financial Results

July 22, 2025

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

July 17, 2025

CareDx Announces Repurchase of 5% of Outstanding Shares

June 2, 2025

CareDx Reports First Quarter 2025 Results

April 29, 2025

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

April 28, 2025

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

April 23, 2025

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

April 20, 2025

CareDx to Report First Quarter 2025 Financial Results

April 7, 2025

CareDx Launches Two Expanded Indications for AlloSure Testing Services

March 10, 2025

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

February 24, 2025

CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients

February 19, 2025

CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies

February 12, 2025

CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025

CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 12, 2025

Calls in 2025

Decks in 2025